BioStar Pharmaceuticals, Inc. Schedules Second Quarter 2011 Earnings Release on August 15, 2011

XIANYANG, China, August 8, 2011 /PRNewswire-Asia/ -- BioStar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("BioStar" or "the Company"), a Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules and a variety of pharmaceutical products, today announced that it will release its unaudited financial results for the second quarter 2011 ended June 30, 2011 before the US market opens on August 15, 2011. It will be followed by a conference call scheduled at 10:30 am EDT on August 15, 2011. Mr. Ronghua Wang, Chief Executive Officer and Chairman of the Board of Directors of the Company, and Mr. Zack Pan, Chief Financial Officer of the Company will be hosting the call.

Conference Call

Please dial in at least 10 minutes before the call to ensure timely participation. Replays of the conference call will be available from 1:30 pm EDT August 15, 2011 till 11:59 pm EDT August 22, 2011 by dialing 1-877-870-5176 (US Toll free) and 1-858-384-5517 (international) and entering "4463197" as the passcode.

This call is also being webcast by ViaVid Broadcasting and can be accessed by clicking on this link: http://viavid.net/dce.aspx?sid=00008AF9 or on the investor relations section of the Company's website http://www.ir-site.com/biostar.

About BioStar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar currently manufactures two broad-based OTC products, two prescription-based pharmaceuticals, one medical device and five health supplements. For more information please visit: http://www.biostarpharmaceuticals.com.

Cautionary Note re: Forward Looking Statements

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under the caption "Item 1A. Risk Factors" in Biostar's most recent Annual Report on Form 10-K filing, as amended to date, and to the extent revised and updated to date in its subsequent Form 10-Q filings. In addition, Biostar operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Biostar disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Biostar's most recent public reports filed with the SEC.